These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

802 related items for PubMed ID: 16584297

  • 1. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V, Gimmnich P, Hofmann HP, Grebe C, Römmele M, Leja A, Baudler M, Benimetskaya L, Gonser B, Pieles U, Maier T, Wagner T, Sanders K, Beck JF, Hanauer G, Stein CA.
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
    Wacheck V, Krepler C, Strommer S, Heere-Ress E, Klem R, Pehamberger H, Eichler HG, Jansen B.
    Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
    [Abstract] [Full Text] [Related]

  • 3. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B, Jox R, Mühlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G.
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [Abstract] [Full Text] [Related]

  • 4. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T, Müller M, Monia BP, Fabbro D.
    Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
    [Abstract] [Full Text] [Related]

  • 6. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
    Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Ménard S, Melani C, Delia D, Zaffaroni N, Pratesi G, Uva V, Tagliabue E, Balsari A.
    Cancer Res; 2011 Oct 15; 71(20):6382-90. PubMed ID: 21878529
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
    Uchida T, Gao JP, Wang C, Satoh T, Itoh I, Muramoto M, Hyodo T, Irie A, Akahoshi T, Jiang SX, Kameya T, Baba S.
    Mol Urol; 2001 Oct 15; 5(2):71-8. PubMed ID: 11690551
    [Abstract] [Full Text] [Related]

  • 8. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
    Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM.
    J Immunol; 2000 Feb 01; 164(3):1617-24. PubMed ID: 10640783
    [Abstract] [Full Text] [Related]

  • 9. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
    Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ.
    Blood; 1997 Apr 15; 89(8):2994-8. PubMed ID: 9108420
    [Abstract] [Full Text] [Related]

  • 10. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May 15; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 11. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
    Lacy J, Loomis R, Grill S, Srimatkandada P, Carbone R, Cheng YC.
    Int J Cancer; 2006 Jul 15; 119(2):309-16. PubMed ID: 16477627
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE.
    J Clin Oncol; 2004 Mar 15; 22(6):1110-7. PubMed ID: 15020613
    [Abstract] [Full Text] [Related]

  • 13. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
    De Cesare M, Calcaterra C, Pratesi G, Gatti L, Zunino F, Mènard S, Balsari A.
    Clin Cancer Res; 2008 Sep 01; 14(17):5512-8. PubMed ID: 18765543
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
    Spugnini EP, Biroccio A, De Mori R, Scarsella M, D'Angelo C, Baldi A, Leonetti C.
    J Transl Med; 2011 Jul 28; 9():125. PubMed ID: 21798045
    [Abstract] [Full Text] [Related]

  • 16. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C, An M, Li M, Liu H.
    Mol Pharm; 2017 Aug 07; 14(8):2815-2823. PubMed ID: 28686452
    [Abstract] [Full Text] [Related]

  • 17. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
    Hanagata N.
    Int J Nanomedicine; 2012 Aug 07; 7():2181-95. PubMed ID: 22619554
    [Abstract] [Full Text] [Related]

  • 18. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
    De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, Rumio C, Zunino F, Pratesi G, Tagliabue E, Balsari A.
    J Immunother; 2010 Jan 07; 33(1):8-15. PubMed ID: 19952960
    [Abstract] [Full Text] [Related]

  • 19. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, Yuan N, Hope M, Cullis P, Tam Y.
    Cancer Immunol Immunother; 2007 Aug 07; 56(8):1251-64. PubMed ID: 17242927
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G.
    Prostate; 2007 Sep 15; 67(13):1475-85. PubMed ID: 17654511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.